Fig. 5: Changes in exploratory outcomes—VBM analyses at 52 weeks.
From: Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial
Panel a shows reduced voxel-wise decline of gray matter VBM in participants treated with liraglutide. VBM analyses are reported for frontal lobe (b), hippocampus (c), medial temporal lobe (d), parietal lobe (e), temporal lobe (f), whole gray matter (g) and whole white matter (h). (i) Figure shows change of scores at 52 weeks at the group level. Data are presented as mean ± s.e.m. (ii) Box plots show the median (center line) and interquartile range (IQR; box limits). Whiskers show the 95% confidence intervals (CIs), and points beyond this range are plotted as outliers. Individual data spread is plotted on the box-and-whiskers plot. Analysis of covariance adjusted for baseline values and stratification factors (age and MMSE) was used to compare between the placebo and liraglutide treatments. Baseline n (placebo, 101; treatment, 101) and 52 weeks n (placebo, 83; treatment, 75). P values are unadjusted (P < 0.05).
